JPMorgan analyst Jessica Fye raised the firm’s price target on Legend Biotech (LEGN) to $78 from $77 and keeps an Overweight rating on the shares. The firm updated the company’s model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEGN:
- Legend Biotech Appoints Carlos Santos as CFO to Drive Financial Strategy
- Legend Biotech appoints Santos as Chief Financial Officer
- Legend Biotech’s Earnings Call: Growth and Success
- Legend Biotech price target raised to $77 from $75 at RBC Capital
- Positive Outlook for Legend Biotech: Strong Sales Growth and Strategic Advancements Drive Buy Rating